Merck's $6 Billion Bid for Terns Pharma Signals Bold Oncology Push 
UK Consumer Confidence Weakens Amid Middle East Conflict and Rising Living Costs 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Gold is meant to be a ‘safe haven’ in uncertain times. Why is it crashing amid a war? 
Finnair Orders 18 Embraer E195-E2 Jets in Landmark Fleet Overhaul 
Oil Prices Climb as Iran Reviews U.S. Peace Proposal Amid Middle East Tensions 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Federal Reserve Balance Sheet Reduction: Brookings Research Outlines Possible Path Forward 
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence 
Currency Markets Show Caution Amid U.S.-Iran Negotiations 
U.S. Stock Futures Steady as Iran Reviews U.S. Ceasefire Proposal 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
WTO Reform Talks Begin in Cameroon Amid Global Trade Tensions 
Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Asian Stocks Gain Amid Iran Conflict Uncertainty 
Moderna Inc. enters a historic $1 billion deal with China to research, develop, and produce exclusive mRNA medicines in the country. The agreement, announced amid growing Sino-American tensions, signifies Beijing's increasing openness to foreign pharmaceutical involvement.
The Cambridge, Massachusetts-based pharmaceutical and biotechnology company announced the new deal with Chinese officials on Wednesday, July 5. The agreement is for Moderna to research, develop and produce messenger RNA medicines in the country.
CNBC noted that an agreement was reached despite the growing tensions between China and the United States. Moderna and Beijing signed a memorandum of understanding (MOU) and land collaboration deal to develop drugs that will be made "exclusively for the Chinese people." This means the two sides agreed that the new drug would never be exported and remain in China.
A local media publication reported earlier this week that Moderna is set to invest about $1 billion in the project. It was added that Moderna's chief executive officer, Stephane Bancel, is set to visit Shanghai, possibly to talk more about the deal and for facility inspection.
"These agreements are focused on strengthening health security by targeting unmet needs and contributing to the ecosystem of medical solutions available to patients in China," the company's spokesman stated.
In a separate statement that was sent to Yahoo Finance, Moderna said, "We signed a memorandum of understanding and a related land collaboration agreement to work toward opportunities for Moderna to research, develop and manufacture mRNA medicines in China."
The deal shows that Moderna is trying to take advantage of the success of its COVID-19 vaccine that has been used on people worldwide. The vaccine used a platform called mRNA to push human cells to make an immune response against a virus. At any rate, the agreement was sealed on Wednesday, and this is Moderna's very first deal with the Chinese government.
Photo by: Ian Hutchinson/Unsplash
